絞り込み

16548

広告

Elotuzumab Plus Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Extended 4-Year Follow-Up and Analysis of Relative Progression-Free Survival From the Randomized ELOQUENT-2 Trial.

著者 Dimopoulos MA , Lonial S , Betts KA , Chen C , Zichlin ML , Brun A , Signorovitch JE , Makenbaeva D , Mekan S , Sy O , Weisel K , Richardson PG
Cancer.2018 Sep 11 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (56view , 0users)
The randomized phase 3 ELOQUENT-2 study (NCT01239797) evaluated the efficacy and safety of elotuzumab plus lenalidomide and dexamethasone (ELd) versus lenalidomide and dexamethasone (Ld) in relapsed/refractory multiple myeloma (RRMM), and to date, has the longest follow-up of any monoclonal antibody in patients with RRMM.
PMID: 30204239 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード